Screener
Ionis Pharmaceuticals IONS Total stock-based compensation expense included in “Total costs and expenses”
Total stock-based compensation expense included in “Total costs and expenses” at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | $$176 | $610 | $323 | 710 |
| Research, development and patent expense | 25,098 | 19,542 | 49,804 | 39,840 |
| Selling, general and administrative expense | 20,321 | 9,538 | 38,743 | 18,858 |
| Stock-based compensation expense, net of amounts capitalized | 45,595 | 29,690 | 88,870 | 59,408 |
| Capitalized stock-based compensation expense | - | 509 | 18 | 1,000 |
| Total stock-based compensation expense | $$45,595 | $30,199 | $88,888 | 60,408 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's total stock-based compensation expense included in “total costs and expenses”?
- Ionis Pharmaceuticals (IONS) reported total stock-based compensation expense included in “total costs and expenses” of $45.6M in Q2 2026.
- How has Ionis Pharmaceuticals's total stock-based compensation expense included in “total costs and expenses” changed year-over-year?
- Ionis Pharmaceuticals's total stock-based compensation expense included in “total costs and expenses” increased by 51.0% year-over-year, from $30.2M to $45.6M.
- What is the long-term trend for Ionis Pharmaceuticals's total stock-based compensation expense included in “total costs and expenses”?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's total stock-based compensation expense included in “total costs and expenses” has grown at a 13.2% compound annual growth rate (CAGR), from $105.81M to $135.66M.
- What does total stock-based compensation expense included in “total costs and expenses” mean?
- The total non-cash expense recognized for equity-based awards granted to employees and directors, such as stock options or restricted stock units. This metric reflects the cost of using equity as a form of compensation to attract and retain talent. It is a critical component of total compensation expense that does not impact cash flow.
Ask your AI about Ionis Pharmaceuticals's total stock-based compensation expense included in “total costs and expenses”.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude